Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary autologous bone marrow mononuclear stem cell injection for children with dilated cardiomyopathy
IRCT20100212003331N2Phase 3Recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jan 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in dilated cardiomyopathy (DCM), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Cardiac function by ejection fraction and Cardiac function by speckle tracking. Started Jan 2022; status: recruiting.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on IRCT20100212003331N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100212003331N2.